Latest Monoclonal antibodies Stories
ReportsnReports.com adds Rheumatoid Arthritis Global Clinical Trials Review H2 2014 to its store.
-- Tanibirumab is a novel VEGFR2-neutralizing mAb for treating cancers SHENYANG, China and DAEJEON, Korea, Nov.
MAB242P, the most recently developed antibody, is the first MBS antibody to recognize both GI and GII strains of norovirus.
Sales of Biologics Will Contribute Approximately $2.3 Billion to the UC Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.
Conference call today at 4:30 p.m. EST MONROVIA, Calif., Nov. 10, 2014 /PRNewswire/ -- Xencor Inc.
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
Drug Developers will Rely on Head-to-Head Clinical Trial Data Against Current Therapies to be Poised to Compete in the Increasingly Crowded TNF-alpha-Refractory Space BURLINGTON, Mass., Nov.
MONROVIA, Calif., Nov. 4, 2014 /PRNewswire/ -- Xencor, Inc.
DALLAS, November 3, 2014 /PRNewswire/ -- According to the new market research report The "Single Use Bioreactor Market by Product Type (Recombinant Proteins, Monoclonal
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.
More Images (1 images) »